These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 19743942

  • 21. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [Abstract] [Full Text] [Related]

  • 22. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C, Chan AT, Tramontano AC, Gazelle GS.
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S.
    Pharmacoeconomics; 2004 Jun; 22(10):643-60. PubMed ID: 15244490
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM, Hindley CE.
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [Abstract] [Full Text] [Related]

  • 31. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 32. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C, Soen S.
    Digestion; 2011 Aug; 83(1-2):108-23. PubMed ID: 21042022
    [Abstract] [Full Text] [Related]

  • 34. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group.
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [Abstract] [Full Text] [Related]

  • 35. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR, Essex MN, Zhang R.
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [Abstract] [Full Text] [Related]

  • 36. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
    Hur C, Simon LS, Gazelle GS.
    Cancer; 2004 Jul 01; 101(1):189-97. PubMed ID: 15222006
    [Abstract] [Full Text] [Related]

  • 37. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.
    Lancet; 2010 Jul 17; 376(9736):173-9. PubMed ID: 20638563
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Kellner HL, Li C, Essex MN.
    Curr Med Res Opin; 2012 Sep 17; 28(9):1537-45. PubMed ID: 22852870
    [Abstract] [Full Text] [Related]

  • 39. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC.
    Semin Arthritis Rheum; 2002 Dec 17; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [Abstract] [Full Text] [Related]

  • 40. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
    Brereton N, Winn B, Akehurst R.
    J Med Econ; 2012 Dec 17; 15(3):465-72. PubMed ID: 22260652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.